Dyslipidemia

Dyslipidemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
Aveo Pharmaceuticals, Inc.
May 18, 2017 - N°20170137506

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use ...
Pharmaceutical compositions of berberine with epa and dha, and methods thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
May 18, 2017 - N°20170135995

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, ...
Implantable electroacupuncture system and method for treating dyslipidemia and obesity
Valencia Technologies Corporation
May 18, 2017 - N°20170135898

An exemplary method of treating obesity or dyslipidemia of a patient includes 1) generating, by an electroacupuncture device implanted beneath a skin surface of the patient, stimulation sessions at a duty cycle that is less than 0. 05, and 2) applying, by the electroacupuncture device in accordance with the duty cycle, the stimulation sessions to at least one of a saphenous nerve and a ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing ...
Hyundai Pharm Co., Ltd.
April 27, 2017 - N°20170114072

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (camp) by activating g protein-coupled receptor 119 (gpr-119) and simultaneously exhibits weight loss and hypoglycemic effects ...
Therapeutic agent for dyslipidemia
Kowa Company, Ltd.
April 27, 2017 - N°20170112811

The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low hdl blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. Which comprises (a) a compound represented by the general formula (1) (in the ...
Novel compounds as diacylglycerol acyltransferase inhibitors
Glaxosmithkline Llc
March 23, 2017 - N°20170081342

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
Esperion Therapeutics, Inc.
March 16, 2017 - N°20170073286

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination ...
Treatment of metabolic disorders in equine animals
Boehringer Ingelheim Vetmedica Gmbh
March 16, 2017 - N°20170071969

A sglt2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a sglt2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic ...
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
Novartis Ag
March 09, 2017 - N°20170065678

The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e. G. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, ...
Methods for treating metabolic disorders using fgf
Salk Institute For Biological Studies
March 02, 2017 - N°20170056475

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
Methods and compositions for increasing fertility and/or inhibiting pregnancy failure and restoring glucose tolerance
Queens University At Kingston
February 23, 2017 - N°20170049753

Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure, restoring glucose tolerance and/or preventing glucose intolerance and/or maintaining glucose homeostasis and/or increasing insulin sensitivity and/or preventing weight gain and/or inducing or enhancing weight loss, treating dyslipidemia, treating hypertestosteronism or hyperandrogenism, and/or treating type 2 diabetes in an individual in need thereof are provided.
Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated ...
Vanderbilt University
February 16, 2017 - N°20170042964

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject. Compositions and methods including a nuclear transport modifier may ...
Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
February 09, 2017 - N°20170037043

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related ...
Sanofi
January 26, 2017 - N°20170022198

The substituted fused heterocyclic compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
Sanofi
January 26, 2017 - N°20170022182

The present invention relates to isoindolinone compounds. The isoindolinone compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
Composition for treatment of dyslipidemia and inflammation
Thorne Research, Inc.
January 19, 2017 - N°20170014374

The present invention provides compositions that are substantially niacin free for treating dyslipidemia and/or inflammation in a subject. Compositions of the invention include a therapeutically effective amount of a mixture phytosomes obtained from quercetin and at least one other phytosome obtained from the group consisting of curcurmin, green tea, and a combination thereof. The present invention also provides a ...
Methods of treating mixed dyslipidemia
Amarin Pharmaceuticals Ireland Limited
January 19, 2017 - N°20170014366

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
Daiichi Sankyo Company, Limited
December 29, 2016 - N°20160376267

A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke ...
Treatment of metabolic disorders in canine animals
Boehringer Ingelheim Vetmedica Gmbh
December 15, 2016 - N°20160361289

The present invention relates to one or more sglt2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia ...
Combination formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor
Cj Healthcare Corporation
December 15, 2016 - N°20160361278

The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an hmg-coa reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an hmg-coa reductase inhibitor, and has effectively improved stability by blocking physical and chemical reactions between ...
Methods for treating metabolic disorders using fgf
Salk Institute For Biological Studies
December 08, 2016 - N°20160354440

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.